Spots Global Cancer Trial Database for nevoid basal cell carcinoma syndrome

Every month we try and update this database with for nevoid basal cell carcinoma syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome	NCT04893486	BCCs in Gorlin ...	PTX-022 Vehicle compara...	18 Years -	Palvella Therapeutics, Inc.
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.	NCT00049959	Basal Cell Carc... Nevoid Basal Ce... Gorlin Syndrome	verteporfin PDT	18 Years - 90 Years	QLT Inc.
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients	NCT02762084	Basal Cell Nevu...	Patidegib Vehicle gel	18 Years - 85 Years	PellePharm, Inc.
Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)	NCT03070691	Basal Cell Carc...	LDE225B Vehicle	18 Years -	Novartis
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)	NCT04308395	Basal Cell Nevu...	Patidegib Topic...	18 Years -	Sol-Gel Technologies, Ltd.
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.	NCT00049959	Basal Cell Carc... Nevoid Basal Ce... Gorlin Syndrome	verteporfin PDT	18 Years - 90 Years	QLT Inc.
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face	NCT00489086	Neoplastic Synd...	tazarotene	18 Years - 75 Years	UCSF Benioff Children's Hospital Oakland
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)	NCT03703310	Basal Cell Nevu...	Patidegib Topic... Patidegib Topic...	18 Years -	PellePharm, Inc.
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back	NCT00783965	Skin Carcinoma	tazarotene placebo	18 Years - 75 Years	UCSF Benioff Children's Hospital Oakland
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face	NCT00489086	Neoplastic Synd...	tazarotene	18 Years - 75 Years	UCSF Benioff Children's Hospital Oakland
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back	NCT00783965	Skin Carcinoma	tazarotene placebo	18 Years - 75 Years	UCSF Benioff Children's Hospital Oakland
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas	NCT02828111	Basal Cell Carc...	Patidegib Vehicle gel	18 Years - 85 Years	PellePharm, Inc.
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas	NCT02828111	Basal Cell Carc...	Patidegib Vehicle gel	18 Years - 85 Years	PellePharm, Inc.
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)	NCT01350115	Basal Cell Carc... Gorlin Syndrome Nevoid Basal Ce...	LDE225 Placebo	18 Years -	Novartis
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants	NCT00433485	Neoplastic Synd... Non-melanomatou...	sirolimus comparative gen... gene expression... microarray anal... protein express... proteomic profi... laboratory biom... mass spectromet... biopsy	18 Years - 120 Years	Yale University
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome	NCT04893486	BCCs in Gorlin ...	PTX-022 Vehicle compara...	18 Years -	Palvella Therapeutics, Inc.
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)	NCT04308395	Basal Cell Nevu...	Patidegib Topic...	18 Years -	Sol-Gel Technologies, Ltd.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: